StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.34+0.02 (+0.86%)

Close on Nov 18, 2026Market cap $138.28MP/E –Yield –

Protara Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Protara Therapeutics's price to book ratio was 1.0× on Nov 11, 2026, against 2.2× a year earlier. Over the last 5 years it ranged from 0.2× to 2.2×, with a median of 0.4×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.0×−0.6
2025Dec 31, 20251.6×+0.2
2024Dec 31, 20241.3×+1.1
2023Dec 29, 20230.3×+0.1
2022Dec 30, 20220.2×−0.2
2021Dec 31, 20210.4×−0.9
2020Dec 31, 20201.3×−26.9
2019Dec 31, 201928.2×+26.4
2018Dec 31, 20181.8×+0.9
2017Dec 29, 20170.8×+0.1
2016Dec 30, 20160.7×−3.0
2015Dec 31, 20153.7×–

More Protara Therapeutics figures

See a number that looks wrong?